Anixa Biosciences, Inc. (NASDAQ:ANIX) Sees Large Drop in Short Interest

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 369,000 shares, a decline of 10.3% from the November 15th total of 411,600 shares. Approximately 1.2% of the shares of the company are short sold. Based on an average daily volume of 89,100 shares, the days-to-cover ratio is presently 4.1 days.

Wall Street Analysts Forecast Growth

ANIX has been the subject of several analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. International Assets Investment Management LLC raised its holdings in shares of Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company's stock valued at $1,190,000 after buying an additional 23,800 shares in the last quarter. Westside Investment Management Inc. grew its position in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company's stock valued at $110,000 after acquiring an additional 21,100 shares during the last quarter. Tyler Stone Wealth Management raised its stake in shares of Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company's stock worth $132,000 after acquiring an additional 21,008 shares in the last quarter. Concorde Asset Management LLC bought a new stake in shares of Anixa Biosciences in the 2nd quarter worth approximately $31,000. Finally, Virtu Financial LLC bought a new stake in shares of Anixa Biosciences in the 3rd quarter worth approximately $34,000. Institutional investors own 29.13% of the company's stock.

Anixa Biosciences Stock Down 2.7 %

NASDAQ:ANIX traded down $0.08 during trading hours on Friday, hitting $2.85. 51,348 shares of the company's stock traded hands, compared to its average volume of 109,167. Anixa Biosciences has a 52 week low of $2.14 and a 52 week high of $5.13. The business's fifty day simple moving average is $3.22 and its two-hundred day simple moving average is $3.04. The firm has a market cap of $91.71 million, a P/E ratio of -7.31 and a beta of 0.82.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.